These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors. Xu QY; Yu L Chin Med J (Engl); 2020 Mar; 133(6):699-715. PubMed ID: 32044818 [TBL] [Abstract][Full Text] [Related]
6. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Sultana F; Manasa KL; Shaik SP; Bonam SR; Kamal A Curr Med Chem; 2019; 26(40):7212-7280. PubMed ID: 29852860 [TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Inhibitors as Anticancer Drugs. Eckschlager T; Plch J; Stiborova M; Hrabeta J Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573 [TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors as cancer therapeutics. Clawson GA Ann Transl Med; 2016 Aug; 4(15):287. PubMed ID: 27568481 [TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach. Ranganna K; Selvam C; Shivachar A; Yousefipour Z Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762 [TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Kim HJ; Bae SC Am J Transl Res; 2011 Feb; 3(2):166-79. PubMed ID: 21416059 [TBL] [Abstract][Full Text] [Related]
11. Histone Deacetylase Inhibitors as Cognitive Enhancers and Modifiers of Mood and Behavior. Pal D; Sahu P; Mishra AK; Hagelgans A; Sukocheva O Curr Drug Targets; 2023; 24(9):728-750. PubMed ID: 36475351 [TBL] [Abstract][Full Text] [Related]
12. HDAC inhibitors as epigenetic regulators for cancer immunotherapy. Conte M; De Palma R; Altucci L Int J Biochem Cell Biol; 2018 May; 98():65-74. PubMed ID: 29535070 [TBL] [Abstract][Full Text] [Related]
13. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. Park J; Thomas S; Munster PN Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer. Lian B; Chen X; Shen K Front Immunol; 2023; 14():1164514. PubMed ID: 36969235 [TBL] [Abstract][Full Text] [Related]
15. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer. Bai Y; Ahmad D; Wang T; Cui G; Li W Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256 [TBL] [Abstract][Full Text] [Related]
16. Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Kopljar I; Gallacher DJ; De Bondt A; Cougnaud L; Vlaminckx E; Van den Wyngaert I; Lu HR Stem Cells Transl Med; 2016 May; 5(5):602-12. PubMed ID: 27034410 [TBL] [Abstract][Full Text] [Related]
17. Mechanism of Action for HDAC Inhibitors-Insights from Omics Approaches. Li W; Sun Z Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30939743 [TBL] [Abstract][Full Text] [Related]
18. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Gameiro SR; Malamas AS; Tsang KY; Ferrone S; Hodge JW Oncotarget; 2016 Feb; 7(7):7390-402. PubMed ID: 26862729 [TBL] [Abstract][Full Text] [Related]
19. Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers. Gracia-Hernandez M; Munoz Z; Villagra A Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944799 [TBL] [Abstract][Full Text] [Related]